Monitoring compliance with antituberculous treatment by detection of isoniazid in urine

Lancet

Volumn 350, Issue 9086, 1997, Pages 1225-1226

  Elizaga, Jorge ^b   Friedland, Jon S ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

ADULT; DRUG COMBINATION; FEMALE; HUMAN; LETTER; MALE; PATIENT COMPLIANCE; TUBERCULOSIS; URINE;

ADULT; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISONIAZID; MALE; PATIENT COMPLIANCE; TUBERCULOSIS;

EID: 0031586438     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(05)63457-5     Document Type: Article

References (5)

1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-76.
2. China Tuberculosis Control Collaboration. Results of directly observed short-course chemotherapy in 112 842 Chinese patients with smear-positive tuberculosis. Lancet 1996; 347: 358-62.
3. London HWG, Prasad J. Tolerance of rifampicin. BMJ 1970; ii: 51.
4. Schraufhagel DE, Stoner R, Whiting E, Snukst-Torbeck G, Werhane MJ. Testing for isoniazid: an evaluation of the Arkansas method. Chest 1990; 98: 314-16.
5. Eidus L, Hamilton EJ. A new method for the determination of N-acetyl isoniazid in urine ambulatory patients. Am Rev Respir Dis 1964; 89: 587-88.